Submitting a pharmaceutical product to multiple global markets is a regulatory challenge, especially when regions like ASEAN and the European Union have differing expectations. This case study explores a successful dual market submission that aligned the stability testing protocols of the ASEAN region (Zone IVb) with EMA’s expectations (Zone II). We examine how the company overcame regional hurdles and streamlined documentation using ICH principles and robust planning.
Background: The Product and Its Markets
A mid-sized European pharmaceutical company planned to launch a solid oral generic in both:
- 📌 The European Union (EU) via EMA centralized procedure
- 📌 Five ASEAN countries including Malaysia, Vietnam, and the Philippines
Though both markets accept ICH guidelines, specific local expectations—such as climatic zones and packaging specifications—posed challenges.
Challenge 1: Divergent Climatic Requirements
The EMA mandates stability studies under ICH Zone II conditions (25°C ± 2°C / 60% RH ± 5%), while ASEAN countries require Zone IVb (30°C ± 2°C /
Initial Issue: The company had only conducted Zone II long-term and accelerated studies. ASEAN regulators rejected this as insufficient for approval.
Solution:
- ✅ Conducted additional real-time studies for Zone IVb on three production-scale batches
- ✅ Bracketing justified for different fill counts based on EMA’s acceptance
- ✅ Accelerated
Challenge 2: Packaging Variation and Moisture Sensitivity
The product was packaged in two configurations:
- 📦 PVC/Alu blister (EU market)
- 📦 HDPE bottle with desiccant (ASEAN market)
Due to differing water vapor transmission rates, ASEAN required full data in the HDPE pack under Zone IVb. EMA was willing to accept data from the PVC/Alu pack as representative.
Resolution:
- ✅ Separate batch allocation for each pack type with stability arms under respective zones
- ✅ Added discussion on packaging permeability and risk assessment in CTD Module 3.2.P.2
Challenge 3: Shelf Life Justification Across Zones
EMA allows extrapolation up to 36 months with 6-month accelerated and 12-month real-time data, while ASEAN prefers 18-month real-time data before granting 24-month shelf life.
Strategy:
- ✅ Proposed 24-month shelf life for both markets
- ✅ Provided interim data trends with commitment to submit 18-month data post-approval in ASEAN
- ✅ Included risk-based justification using ICH Q1E linear regression modeling
This dual approach satisfied both EMA reviewers and ASEAN regulators, as supported by aligned regulatory compliance strategies.
Challenge 4: Protocol Harmonization in CTD Format
To avoid duplication, the team developed a single master protocol that included annexes for:
- ✅ Zone-specific storage conditions
- ✅ Country-specific packaging
- ✅ Photostability testing per ICH Q1B for EMA
- ✅ In-use and transport studies requested by some ASEAN countries
The protocol referenced SOPs validated per Pharma SOPs, ensuring GxP-compliant execution across both regions.
Challenge 5: Analytical Method Validation Acceptance
Another major roadblock was method validation. EMA reviewers preferred methods validated under ICH Q2(R1), while some ASEAN nations requested additional robustness testing and intermediate precision data under local guidelines.
Actions Taken:
- ✅ Submitted full ICH-compliant method validation reports for assay, degradation products, and dissolution
- ✅ Supplemented with ASEAN-specific robustness testing using a modified mobile phase and column type
- ✅ Highlighted performance consistency in intermediate lab setups to address local regulatory concerns
By proactively addressing method equivalency, both EMA and ASEAN authorities accepted the data without requiring revalidation.
Outcome: Regulatory Approval and Lessons Learned
The coordinated stability strategy led to successful product approvals in both regions within 14 months. Key achievements included:
- 🏆 24-month shelf life granted in both EMA and ASEAN markets
- 🏆 Single stability protocol used with regional annexes
- 🏆 No major queries raised during ASEAN national review cycles
- 🏆 Accepted bridging of packaging data using moisture ingress modeling
Lessons: A harmonized approach built on ICH principles, combined with early dialogue and modular protocol design, can reduce workload and prevent delays during dual-region filings.
Final Recommendations for Dual Market Submissions
To ensure success when targeting both ASEAN and EMA regions, follow these key tips:
- 💡 Initiate Zone IVb stability early if ASEAN is in scope
- 💡 Use separate packs and chambers to capture regional conditions
- 💡 Employ bracketing/matrixing judiciously, with justification
- 💡 Align shelf life justification with ICH Q1E across submissions
- 💡 Create CTD-friendly modular protocols with region-specific annexes
- 💡 Stay informed on evolving expectations through agencies like EMA and WHO
Conclusion: Harmonization Is Achievable with Strategic Planning
Although regional differences in stability testing can seem daunting, this case study shows that a smart, harmonized approach can satisfy both EMA and ASEAN regulatory authorities. By focusing on flexibility in protocol design, zone-specific data generation, and scientific justification for bridging, pharmaceutical companies can reduce approval timelines, eliminate redundant testing, and achieve global market access more efficiently.
Harmonization is not just a regulatory goal—it is a practical strategy for global success in today’s competitive pharmaceutical landscape.